查看購物車
  • Simplified Chinese
  • English
2021-2031年北美抗生素和抗真菌藥物市場報告：範圍、細分、動態和競爭分析
市場調查報告書
商品編碼
1871447

2021-2031年北美抗生素和抗真菌藥物市場報告：範圍、細分、動態和競爭分析

North America Antibiotics & Antimycotics Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 183 Pages | 訂單完成後即時交付

價格

預計北美抗生素和抗真菌藥物市場將大幅成長，到 2031 年將達到約 247.2659 億美元，高於 2023 年的 164.3434 億美元，預測期內年複合成長率(CAGR) 為 5.2%。

執行摘要和市場分析

北美抗生素和抗真菌藥物市場的成長主要受以下因素驅動：傳染病日益流行、人們對抗菌素抗藥性的認知不斷提高以及持續的藥物創新。主要產業參與者正投資研發新的製劑和聯合療法以應對這些挑戰。此外，強力的監管支持和先進的醫療保健體係也促進了市場的擴張。儘管面臨抗藥性和嚴格的核准流程等挑戰，但對有效抗菌治療的需求依然強勁，尤其是在醫院環境和免疫功能低下患者群體中。

市場區隔分析

北美抗生素和抗真菌藥物市場可根據藥物類別、適應症、給藥途徑和配銷通路進行細分：

  • 藥物類別：市場涵蓋多種藥物類別，例如青黴素、頭孢菌素、碳青黴烯類、大環內酯類、氨基糖苷類、喹諾酮類、磺胺類、四環素類、唑類等。 2023年，青黴素佔據最大的市場佔有率。
  • 適應症：市場分為皮膚感染、呼吸道感染、泌尿道感染 (UTI)、敗血症、耳部感染、胃腸道感染和其他感染，其中皮膚感染在 2023 年佔據市場佔有率領先。
  • 給藥途徑：包括口服、外用和其他方法，口服給藥在 2023 年佔據市場主導地位。
  • 配銷通路：市場分為醫院藥房、零售藥房和線上藥房，其中醫院藥房在 2023 年佔據最大佔有率。

市場展望

人們對真菌感染及其嚴重健康後果的認知不斷提高，是推動抗生素和抗真菌藥物市場成長的重要因素。全球真菌感染行動基金（GAFFI）在2023年報告稱，全球有超過3億人患有嚴重的真菌疾病，每年導致約150萬人死亡，超過瘧疾和結核病死亡人數的總和。這一令人擔憂的趨勢促使人們進行廣泛的教育活動，並改善診斷能力，從而提高醫護人員和患者對及時治療必要性的認知。

分子檢測等診斷方法的創新促進了真菌病原體的早期發現，進一步增加了對有效抗真菌治療的需求。美國疾病管制與預防中心 (CDC) 已啟動耳念珠菌監測項目，以提升實驗室能力和疫情管理水準。此外，全球真菌感染與真菌學會 (GAFFI) 的十年消除真菌疾病路線圖強調了有效診斷的必要條件。包括國際人類和動物真菌學會 (ISHAM) 和歐洲疾病預防控制中心 (ECDC) 在內的多個組織也在努力提高公眾對真菌感染負擔的認知，並改善預防、診斷和治療策略。每年9月16日至20日舉行的「真菌疾病宣傳週」旨在提高公眾對真菌疾病日益普遍以及採取適當應對措施必要性的認知。

國家概況

北美抗生素和抗真菌藥物市場主要由美國、加拿大和墨西哥組成，其中美國在2023年佔據最大的市場佔有率。美國市場的成長主要受真菌和細菌感染發病率上升以及對有效治療方案的需求所推動。肺炎是一種常見的呼吸道感染，每年在美國影響約150萬成年人，導致大量住院和死亡病例。阿莫西林和阿奇黴素是門診最常使用的抗生素之一。

藥物研發的不斷進步正在加速新型抗生素和抗真菌藥物的開發，從而應對抗生素抗藥性和創新療法的需求。抗菌藥物管理計畫的推行，促使人們更加謹慎地使用抗生素，尤其是在醫院感染高發生率的環境中。

關鍵參與者

北美抗生素和抗真菌藥物市場的主要公司包括輝瑞公司、諾華公司、賽諾菲公司、羅氏公司、默克公司、葛蘭素史克公司、強生公司、西普拉公司、拜耳公司、艾伯維公司和安斯泰來製藥公司。這些公司正在推行產品上市、核准和合作等策略，以增強其市場佔有率並為消費者提供創新解決方案。

目錄

第1章：引言

第2章：執行概要

  • 關鍵見解

第3章：研究方法

  • 二手研究
  • 初步研究
    • 假設的提出：
    • 宏觀經濟因素分析：
    • 發展基數：
    • 數據三角測量：
    • 國家層面資料：

第4章：北美抗生素和抗真菌藥物市場概況

  • 概述
  • PEST分析

第5章：北美抗生素和抗真菌藥物市場－主要市場動態

  • 市場促進因素
    • 傳染病發生率不斷上升
    • 人們對真菌感染的認知不斷提高
  • 市場限制
    • 抗菌素抗藥性、經濟障礙和繁瑣的監管程序
  • 市場機遇
    • 持續的資金投入與研發計劃
  • 未來趨勢
    • 產品開發和治療輸送方法的技術進步
  • 駕駛員和安全帶的影響：

第6章：抗生素和抗真菌藥物市場——北美分析

  • 2021-2031年北美抗生素和抗真菌藥物市場收入
  • 北美抗生素和抗真菌藥物市場預測分析

第7章：北美抗生素和抗真菌藥物市場分析－按藥物類別分類

  • 青黴素
  • 頭孢菌素
  • 碳青黴烯類
  • 大環內酯類
  • 氨基糖苷類
  • 奎諾酮類
  • 磺胺類藥物
  • 四環素類
  • 唑類
  • 其他

第8章：北美抗生素和抗真菌藥物市場分析－按適應症分類

  • 皮膚感染
  • 呼吸道感染
  • 泌尿道感染（UTI）
  • 敗血症
  • 耳部感染
  • 胃腸道感染
  • 其他

第9章：北美抗生素和抗真菌藥物市場分析－依給藥途徑分類

  • 口服
  • 主題
  • 其他

第10章：北美抗生素和抗真菌藥物市場分析－按配銷通路分類

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第11章：北美抗生素和抗真菌藥物市場——國別分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

第12章：抗生素和抗真菌藥物市場－產業概況

  • 概述
  • 抗生素和抗真菌藥物市場成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第13章：公司簡介

  • Pfizer Inc
  • Novartis AG
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • GSK Plc
  • Johnson & Johnson
  • Cipla Ltd
  • Bayer AG
  • AbbVie Inc
  • Astellas Pharma Inc

第14章：附錄

Product Code: BMIRE00032104

The North America antibiotics and antimycotics market is projected to grow significantly, reaching approximately USD 24,726.59 million by 2031, up from USD 16,434.34 million in 2023, reflecting a compound annual growth rate (CAGR) of 5.2% during the forecast period.

Executive Summary and Market Analysis

The growth of the North American antibiotics and antimycotics market is primarily driven by the increasing prevalence of infectious diseases, heightened awareness regarding antimicrobial resistance, and ongoing pharmaceutical innovations. Major industry players are investing in new formulations and combination therapies to address these challenges. Additionally, robust regulatory support and advanced healthcare systems contribute to the market's expansion. Despite facing hurdles such as drug resistance and stringent approval processes, the demand for effective antimicrobial treatments remains strong, especially in hospital environments and among immunocompromised patients.

Market Segmentation Analysis

The North America antibiotics and antimycotics market can be segmented based on drug class, indication, route of administration, and distribution channel:

  • Drug Class: The market includes various drug classes such as penicillin, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. In 2023, penicillin held the largest market share.
  • Indication: The market is segmented into skin infections, respiratory infections, urinary tract infections (UTI), septicemia, ear infections, gastrointestinal infections, and others, with skin infections leading in market share in 2023.
  • Route of Administration: This includes oral, topical, and other methods, with oral administration dominating the market in 2023.
  • Distribution Channel: The market is divided into hospital pharmacies, retail pharmacies, and online pharmacies, where hospital pharmacies accounted for the largest share in 2023.

Market Outlook

The increasing awareness of fungal infections and their serious health implications is a significant factor driving the growth of the antibiotics and antimycotics market. The Global Action Fund for Fungal Infections (GAFFI) reported in 2023 that over 300 million people globally suffer from severe fungal diseases, leading to approximately 1.5 million deaths annually, surpassing the combined fatalities from malaria and tuberculosis. This alarming trend has prompted extensive educational initiatives and improved diagnostic capabilities, enhancing awareness among healthcare providers and patients about the necessity for timely treatment.

Innovations in diagnostic methods, such as molecular testing, have facilitated the early detection of fungal pathogens, further increasing the demand for effective antifungal treatments. The Centers for Disease Control and Prevention (CDC) has initiated programs to monitor Candida auris, enhancing laboratory capabilities and outbreak management. Furthermore, GAFFI's 10-year roadmap for eliminating fungal diseases emphasizes the essential conditions for effective diagnostics. Various organizations, including the International Society for Human and Animal Mycology (ISHAM) and the European Centre for Disease Prevention and Control (ECDC), are also working to highlight the burden of fungal infections and improve prevention, diagnosis, and treatment strategies. The annual Fungal Disease Awareness Week, observed from September 16-20, aims to raise awareness about the growing prevalence of fungal diseases and the need for appropriate responses.

Country Insights

The North American antibiotics and antimycotics market is primarily composed of the US, Canada, and Mexico, with the US holding the largest market share in 2023. The growth in the US market is fueled by the rising incidence of fungal and bacterial infections and the demand for effective treatment options. Pneumonia, a common respiratory infection, affects approximately 1.5 million adults annually in the US, leading to significant hospital admissions and fatalities. Amoxicillin and azithromycin are among the most frequently prescribed antibiotics in outpatient settings.

Ongoing advancements in pharmaceutical research are accelerating the development of new antibiotics and antifungal agents, addressing concerns about antibiotic resistance and the need for innovative therapies. The emphasis on antimicrobial stewardship programs is promoting a more judicious approach to antibiotic prescriptions, particularly in hospital settings where hospital-acquired infections are prevalent.

Key Players

Prominent companies in the North America antibiotics and antimycotics market include Pfizer Inc., Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc., GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc., and Astellas Pharma Inc. These companies are pursuing strategies such as product launches, approvals, and collaborations to enhance their market presence and offer innovative solutions to consumers.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. North America Antibiotics and Antimycotics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. North America Antibiotics and Antimycotics Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increasing Prevalence of Infectious Diseases
    • 5.1.2 Growing Awareness About Fungal Infections
  • 5.2 Market Restraints
    • 5.2.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
  • 5.3 Market Opportunities
    • 5.3.1 Ongoing Funding and Research & Development Initiatives
  • 5.4 Future Trends
    • 5.4.1 Technological Advancements in Product Development and Treatment Delivery Approaches
  • 5.5 Impact of Drivers and Restraints:

6. Antibiotics and Antimycotics Market - North America Analysis

  • 6.1 North America Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • 6.2 North America Antibiotics and Antimycotics Market Forecast Analysis

7. North America Antibiotics and Antimycotics Market Analysis - by Drug Class

  • 7.1 Penicillin
    • 7.1.1 Overview
    • 7.1.2 Penicillin: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Cephalosporines
    • 7.2.1 Overview
    • 7.2.2 Cephalosporines: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Carbapenems
    • 7.3.1 Overview
    • 7.3.2 Carbapenems: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 Macrolides
    • 7.4.1 Overview
    • 7.4.2 Macrolides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.5 Aminoglycosides
    • 7.5.1 Overview
    • 7.5.2 Aminoglycosides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.6 Quinolones
    • 7.6.1 Overview
    • 7.6.2 Quinolones: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.7 Sulfonamides
    • 7.7.1 Overview
    • 7.7.2 Sulfonamides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.8 Tetracyclines
    • 7.8.1 Overview
    • 7.8.2 Tetracyclines: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.9 Azoles
    • 7.9.1 Overview
    • 7.9.2 Azoles: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.10 Others
    • 7.10.1 Overview
    • 7.10.2 Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. North America Antibiotics and Antimycotics Market Analysis - by Indication

  • 8.1 Skin Infections
    • 8.1.1 Overview
    • 8.1.2 Skin Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Respiratory Infections
    • 8.2.1 Overview
    • 8.2.2 Respiratory Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.3 Urinary Tract Infections (UTI)
    • 8.3.1 Overview
    • 8.3.2 Urinary Tract Infections (UTI): North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.4 Septicemia
    • 8.4.1 Overview
    • 8.4.2 Septicemia: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.5 Ear Infections
    • 8.5.1 Overview
    • 8.5.2 Ear Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.6 Gastrointestinal Infections
    • 8.6.1 Overview
    • 8.6.2 Gastrointestinal Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.7 Others
    • 8.7.1 Overview
    • 8.7.2 Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. North America Antibiotics and Antimycotics Market Analysis - by Route Of Administration

  • 9.1 Oral
    • 9.1.1 Overview
    • 9.1.2 Oral: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 Topical
    • 9.2.1 Overview
    • 9.2.2 Topical: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. North America Antibiotics and Antimycotics Market Analysis - by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Overview
    • 10.1.2 Hospital Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 10.2 Retail Pharmacies
    • 10.2.1 Overview
    • 10.2.2 Retail Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 10.3 Online Pharmacies
    • 10.3.1 Overview
    • 10.3.2 Online Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

11. North America Antibiotics and Antimycotics Market - Country Analysis

  • 11.1 North America
    • 11.1.1 North America Antibiotics and Antimycotics Market Overview
    • 11.1.2 North America Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.1.2.1 North America Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.1.2.2 United States: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 11.1.2.2.1 United States: North America Antibiotics and Antimycotics Market Share - by Drug Class
        • 11.1.2.2.2 United States: North America Antibiotics and Antimycotics Market Share - by Indication
        • 11.1.2.2.3 United States: North America Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 11.1.2.2.4 United States: North America Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 11.1.2.3 Canada: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 11.1.2.3.1 Canada: North America Antibiotics and Antimycotics Market Share - by Drug Class
        • 11.1.2.3.2 Canada: North America Antibiotics and Antimycotics Market Share - by Indication
        • 11.1.2.3.3 Canada: North America Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 11.1.2.3.4 Canada: North America Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 11.1.2.4 Mexico: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 11.1.2.4.1 Mexico: North America Antibiotics and Antimycotics Market Share - by Drug Class
        • 11.1.2.4.2 Mexico: North America Antibiotics and Antimycotics Market Share - by Indication
        • 11.1.2.4.3 Mexico: North America Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 11.1.2.4.4 Mexico: North America Antibiotics and Antimycotics Market Share - by Distribution Channel

12. Antibiotics and Antimycotics Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Antibiotics and Antimycotics Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Pfizer Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Novartis AG
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Sanofi SA
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 F. Hoffmann-La Roche Ltd
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Merck & Co Inc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 GSK Plc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Johnson & Johnson
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Cipla Ltd
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Bayer AG
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 AbbVie Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Astellas Pharma Inc
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. North America Antibiotics and Antimycotics Market Segmentation
  • Table 2. North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 3. North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Drug Class
  • Table 4. North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indication
  • Table 5. North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Route Of Administration
  • Table 6. North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 7. North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 8. United States: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 9. United States: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 10. United States: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 11. United States: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 12. Canada: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 13. Canada: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 14. Canada: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 15. Canada: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 16. Mexico: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 17. Mexico: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 18. Mexico: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 19. Mexico: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 20. Recent Organic Growth Strategies in Antibiotics and Antimycotics Market
  • Table 21. Recent Inorganic Growth Strategies in the Antibiotics and Antimycotics Market
  • Table 22. Glossary of Terms, Antibiotics and Antimycotics Market

List Of Figures

  • Figure 1. North America Antibiotics and Antimycotics Market Segmentation - Country
  • Figure 2. PEST Analysis
  • Figure 3. North America Antibiotics and Antimycotics Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. North America Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • Figure 6. North America Antibiotics and Antimycotics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 7. Penicillin: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Cephalosporines: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Carbapenems: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Macrolides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Aminoglycosides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 12. Quinolones: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Sulfonamides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Tetracyclines: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Azoles: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 17. North America Antibiotics and Antimycotics Market Share (%) - by Indication (2023 and 2031)
  • Figure 18. Skin Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Respiratory Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Urinary Tract Infections (UTI): North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. Septicemia: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Ear Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 23. Gastrointestinal Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 24. Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 25. North America Antibiotics and Antimycotics Market Share (%) - by Route Of Administration (2023 and 2031)
  • Figure 26. Oral: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 27. Topical: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 28. Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 29. North America Antibiotics and Antimycotics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 30. Hospital Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 31. Retail Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 32. Online Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 33. North America Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 34. United States: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 35. Canada: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 36. Mexico: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 37. Growth Strategies in Antibiotics and Antimycotics Market